Although we have only assessed total lipid by 1H-MRS in tumor tissue, it is highly likely that both MYC/N amplified neuroblastoma and medulloblastoma have altered lipid signatures, and that therapeutic targeting of lipid metabolism may offer a potential avenue for directed treatment in these high risk cases. The gene discussed is MYC; the disease is neoplasm.